Omeros (OMER) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with introductions of board members, auditor, and Inspector of Elections, and outlined agenda and rules for Q&A, emphasizing orderly conduct and forward-looking statement disclaimers.

Overview of voting outcomes

• Quorum established with approximately 80% of shares represented.

• Election of three Class II directors approved for terms until 2029.

• Say on Pay resolution and amended Omnibus Incentive Compensation Plan approved.

• Ratification of Ernst & Young as independent auditor for 2026 confirmed.

Financial performance review

• Balance sheet materially strengthened through the Novo Nordisk transaction, providing $240M upfront, $100M near-term milestones, and up to $1.71B in potential milestones and royalties.

• Significant debt retired, leaving only 2029 convertible notes; agreement to repurchase up to $16M in principal announced.

• Company targets positive cash flow by mid-2027, supported by strong working capital.

• YARTEMLEA launch became cash flow positive in Q1 2026.